CN110662536B - 激酶网络抑制剂及其用途 - Google Patents

激酶网络抑制剂及其用途 Download PDF

Info

Publication number
CN110662536B
CN110662536B CN201880034786.5A CN201880034786A CN110662536B CN 110662536 B CN110662536 B CN 110662536B CN 201880034786 A CN201880034786 A CN 201880034786A CN 110662536 B CN110662536 B CN 110662536B
Authority
CN
China
Prior art keywords
tetrahydro
pyrazolo
phenanthridin
esi
found
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880034786.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN110662536A (zh
Inventor
赫尔曼·O·辛蒂姆
尼图·达亚尔
克莱门特·奥波库·特蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of CN110662536A publication Critical patent/CN110662536A/zh
Application granted granted Critical
Publication of CN110662536B publication Critical patent/CN110662536B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880034786.5A 2017-03-29 2018-03-29 激酶网络抑制剂及其用途 Active CN110662536B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762478069P 2017-03-29 2017-03-29
US62/478,069 2017-03-29
US201862616643P 2018-01-12 2018-01-12
US62/616,643 2018-01-12
PCT/US2018/024991 WO2018183586A1 (en) 2017-03-29 2018-03-29 Inhibitors of kinase networks and uses thereof

Publications (2)

Publication Number Publication Date
CN110662536A CN110662536A (zh) 2020-01-07
CN110662536B true CN110662536B (zh) 2023-06-23

Family

ID=63677063

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880034786.5A Active CN110662536B (zh) 2017-03-29 2018-03-29 激酶网络抑制剂及其用途

Country Status (6)

Country Link
US (3) US11040973B2 (https=)
EP (2) EP4233859A1 (https=)
JP (3) JP7788208B2 (https=)
CN (1) CN110662536B (https=)
CA (1) CA3056641A1 (https=)
WO (1) WO2018183586A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040973B2 (en) * 2017-03-29 2021-06-22 Purdue Research Foundation Inhibitors of kinase networks and uses thereof
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
US20220017908A1 (en) * 2018-11-20 2022-01-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease
SG11202104331YA (en) 2018-12-11 2021-05-28 Theravance Biopharma R&D Ip Llc Naphthyridine and quinoline derivatives useful as alk5 inhibitors
WO2021061823A1 (en) * 2019-09-23 2021-04-01 Boragen, Inc. Chemical compounds
CN114728941A (zh) 2019-11-22 2022-07-08 施万生物制药研发Ip有限责任公司 作为alk5抑制剂的经取代的1,5-萘啶或喹啉
CN113214294A (zh) * 2020-06-10 2021-08-06 深圳铂立健医药有限公司 三环化合物、药物组合物及其应用
EP4175637A4 (en) * 2020-07-02 2024-08-07 Purdue Research Foundation Tetrahydro-3h-pyrazolo quinolone and tetrahydro-3h-pyrrolo[3,2-f]quinoline-containing compounds and uses thereof
KR20250004773A (ko) * 2022-04-20 2025-01-08 상하이 지멍 바이오파마 아이엔씨 Rho 관련 단백질 키나아제 억제제 및 이의 제조와 응용
CN117186002A (zh) * 2022-05-31 2023-12-08 江苏亚虹医药科技股份有限公司 7-氰基-8-羟基喹啉衍生物、其制备方法及其医药用途
EP4532471A2 (en) * 2022-06-02 2025-04-09 Purdue Research Foundation 4-(3h-pyrazolo[4,3-f]quinolin-7-yl)-n-(2-(dimethylamino)ethyl)benzamide- or hydroxamic acid compounds, compositions, and methods of use
WO2024206164A1 (en) * 2023-03-24 2024-10-03 Purdue Research Foundation 3H-PYRAZOLO[4.3:f] QUINOLINE-BASED COMPOUNDS AS STING ANTAGONISTS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947434A (en) * 1973-06-06 1976-03-30 Morton-Norwich Products, Inc. 9-(P-phenylazoanilino)-7-methyl-1H-imidazo[4,5-f]quinolines
CA1263378A (en) * 1985-01-08 1989-11-28 Robert James Alaimo Imidazo¬4,5-f|quinolines useful as immunomodulating agents
CA2134448A1 (en) * 1992-05-01 1993-11-02 Yoshinori Kyotani Quinoline derivative or salt thereof and remedy for cardiac diseases containing the same
US6228362B1 (en) * 1992-08-21 2001-05-08 Immunomedics, Inc. Boron neutron capture therapy using pre-targeting methods
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
PL215901B1 (pl) * 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
US20050080260A1 (en) * 2003-04-22 2005-04-14 Mills Randell L. Preparation of prodrugs for selective drug delivery
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060281771A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
CA2598216C (en) * 2005-06-17 2014-04-08 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
WO2007005887A2 (en) * 2005-07-01 2007-01-11 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds, compositions and uses thereof
JPWO2011043359A1 (ja) 2009-10-06 2013-03-04 協和発酵キリン株式会社 芳香族複素環化合物を含有する医薬
JP2013542243A (ja) 2010-11-15 2013-11-21 カトリーケ ウニヴェルシテイト ルーヴェン 新規な抗ウイルス性化合物
US9643965B2 (en) * 2014-09-17 2017-05-09 Celgene Quantical Research, Inc. Histone demethylase inhibitors
EP3242872B1 (en) 2015-01-09 2019-07-03 Genentech, Inc. (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
US11040973B2 (en) * 2017-03-29 2021-06-22 Purdue Research Foundation Inhibitors of kinase networks and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Iodine-catalysed synthesis of thiopyrano[3,4-c]quinoline derivatives via imino-Diels–Alder reaction;Wei Wang等;《JOURNAL OF CHEMICAL RESEARCH》;第318-321页 *
Iodine-Catalyzed Synthesis of Fused Polycyclic Heterocycles Containing Pyrazoloquinoline via PovarovReaction;Wen-Ting Zhang等;《Polycyclic Aromatic Compounds》;第1-11页 *
Synthesis of 7-aryl-9-methyl-3h- pyrazolo[4,3-f]quinoline derivatives catalysed by iodine;Ming-Yue Yin等;《JOURNAL OF CHEMICAL RESEARCH》;第513-515页 *

Also Published As

Publication number Publication date
EP3600287A1 (en) 2020-02-05
US20200308173A1 (en) 2020-10-01
US12384782B2 (en) 2025-08-12
EP3600287B1 (en) 2023-07-05
US20210371420A1 (en) 2021-12-02
JP2022191259A (ja) 2022-12-27
EP4233859A1 (en) 2023-08-30
JP7668254B2 (ja) 2025-04-24
CN110662536A (zh) 2020-01-07
US11891391B2 (en) 2024-02-06
JP2022081529A (ja) 2022-05-31
JP7837179B2 (ja) 2026-03-30
EP3600287A4 (en) 2021-03-31
WO2018183586A1 (en) 2018-10-04
CA3056641A1 (en) 2018-10-04
US11040973B2 (en) 2021-06-22
JP2020523282A (ja) 2020-08-06
US20240208971A1 (en) 2024-06-27
JP7788208B2 (ja) 2025-12-18

Similar Documents

Publication Publication Date Title
CN110662536B (zh) 激酶网络抑制剂及其用途
US9962382B2 (en) Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
CN101679425B (zh) 6-(吡咯并吡啶基)嘧啶-2-基胺及其治疗癌症和艾滋病的用途
EP2651888B1 (en) N-((1H-indol-3-yl)-alkyl)-4-benzyl)benzamide and N-((1H-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders
US20090275570A1 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
TW201247665A (en) Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent
KR101921764B1 (ko) 피라졸로-퀴놀린
SG183855A1 (en) Morpholinylquinazolines
WO2008157791A2 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
US20260015341A1 (en) Pi3k inhibitor, preparation method therefor, and use thereof
CA2982862A1 (en) Preparation and use of kinase inhibitor
CN119255992A (zh) 杂环衍生物及其组合物和应用
TWI386411B (zh) １，４-二氫吡啶稠合雜環，其製備方法、用途及包含其之組合物
CN111153891B (zh) 一种取代苯并咪唑类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用
WO2023185073A1 (zh) Parp7抑制剂及其用途
WO2020156319A1 (zh) N-甲酰胺衍生物、其制备方法及其在医药上的用途
CN112625027B (zh) 杂环衍生物及其用途
TWI759829B (zh) 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
WO2026060099A1 (en) Selective pi3k inhibitors
CN121949337A (zh) 靶向泛素化降解alk的化合物及其药物组合物
CN117024441A (zh) 一种mat2a抑制剂
AU2010313240A1 (en) Kinase inhibitors
HK1192224B (en) N-((1h-indol-3-yl)-alkyl)-4-benzyl)benzamide and n-((1h-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders
HK1192224A (en) N-((1h-indol-3-yl)-alkyl)-4-benzyl)benzamide and n-((1h-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant